Clinical Trial Search

Primary: R0 Resection Rates in Each Cohort as Measured by Macroscopically Complete Tumor Removal With Negative Microscopic Surgical Margins — 9; 9 participants with resectable PDAC

Primary: Nonfunctioning and Malignant Pancreatic Endocrine Neoplasms — 28; 12; 22; 18 participants

Primary: 60-day ≥ Grade II Complication Rate — 72; 76 Participants — p=0.804

Primary: Number of Subjects Completing Therapy Including Surgical Resection. — 107 Participants

Primary: Feasibility as Measured by Number of Participants Who Complete the Neoadjuvant Gemcitabine/Nab-paclitaxel and HIGRT Regimen — 39 Participants

Primary: Number of Participants With Resectability Rate — 15 Participants

Primary: Survival — 37; 31 participants

Primary: Median Overall Survival of Patients With Adenocarcinoma of the Pancreas — 31.6 months

Primary: Biochemical Response Rate — 383; 550; 43; 53 U/mL

Primary: The Percentage of Patients That Underwent an R0 Resection — 52 percentage of patients

Primary: Rate of Margin Negative Surgical Resection (R0 Resection Rate) — 88 percentage of participants

Primary: Percentage of Patients With Pathologic Complete Response — 0 percentage of participants

Primary: Frequency of R0 Resection — 11; 2 Participants

Primary: Percentage Able to Complete Full Course of Preoperative Chemotherapy — 22 Participants

Primary: Local Progression-free Survival (LPFS) — 22.30801 months

Primary: Dose Limiting Toxicities — 0; 0; 1; 3 Participants

Primary: Number of Participants With Acute (Within 3 Months of Treatment) Grade 3 or Greater Gastrointestinal Toxicity — 0 Participants

Primary: Number of Serious Pre-operative, Operative and Post-operative Adverse Events to 120 Days Post Randomization or to 30 Days Post Surgery, Whichever Comes Last — 40; 36…

Primary: Sensitivity of [68Ga]FAPI-46 PET Imaging to Detect PDAC, Using Histopathology as Truth Standard — 0.741 proportion of participants

Primary: Recurrence Free Survival — 15.6 months

Primary: Percent of Patients Experiencing an Unacceptable Toxicity — 6.67; 6.67 Percentage of Participants

Primary: Local Progression-free Survival (LPFS) at 1-year — 85 percentage of participants

Primary: Overall Survival at 18 Months — 63 percentage of participants

Primary: Overall Survival — 24.8 Months

Primary: CA 19-9 Normalization — 40; 13.6; 30; 50 Percentage of participants — p=0.235

Primary: Maximal Tolerated Dose (MTD) & Dose Limiting Toxicity (DLT) of Intratumoral Injections of BC-819 — 0; 1 participants

Primary: SUVmax (Maximal Standard Uptake Value) Measurement 30 and 90 Min p.i. (Post Injection) — 0.77; 0.78; 0.81; 0.8 SUVmax — p=0.78

Primary: Number of Participants With Dose Limiting Toxicity (DLT ) — 0; 1; 0; 0 Participants

Primary: To Determine the Sensitivity High Resolution Magnetic Resonance Imaging With Lymphotrophic Superparamagnetic Nanoparticles to Identify Small and Otherwise Undetectable…

Primary: Overall Survival — 17.25; 17.94 months — p=0.5487